Gossamer Bio Stock Net Income

GOSS Stock  USD 2.73  0.00  0.00%   
As of the 26th of January, Gossamer Bio retains the Market Risk Adjusted Performance of 0.2861, downside deviation of 5.04, and Risk Adjusted Performance of 0.0638. Gossamer Bio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Gossamer Bio variance and potential upside to decide if Gossamer Bio is priced fairly, providing market reflects its last-minute price of 2.73 per share. Please also validate Gossamer Bio total risk alpha, which is currently at (0.10) to confirm the company can sustain itself at a future point.

Gossamer Bio Total Revenue

138.5 Million

Gossamer Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Gossamer Bio's valuation are provided below:
Gross Profit
44.1 M
Market Capitalization
624.9 M
Enterprise Value Revenue
14.7008
Revenue
44.1 M
Earnings Share
(0.69)
There are over one hundred nineteen available fundamental trends for Gossamer Bio, which can be analyzed over time and compared to other ratios. All traders should confirm Gossamer Bio's regular fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to gain to about 610.9 M in 2026, whereas Market Cap is likely to drop slightly above 223.6 M in 2026. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
Last ReportedProjected for Next Year
Net Loss-50.9 M-53.4 M
Net Loss-206.4 M-216.8 M
Net Loss-50.9 M-53.4 M
Net Loss(0.29)(0.30)
Net Income Per E B T 0.91  0.81 
Net Loss is likely to drop to about (53.4 M) in 2026. Net Loss is likely to drop to about (216.8 M) in 2026.
  
Build AI portfolio with Gossamer Stock

Latest Gossamer Bio's Net Income Growth Pattern

Below is the plot of the Net Income of Gossamer Bio over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Gossamer Bio financial statement analysis. It represents the amount of money remaining after all of Gossamer Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Gossamer Bio's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gossamer Bio's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (56.53 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

Gossamer Net Income Regression Statistics

Arithmetic Mean(81,324,715)
Coefficient Of Variation(118.85)
Mean Deviation85,458,554
Median(50,875,200)
Standard Deviation96,655,167
Sample Variance9342.2T
Range243.3M
R-Value(0.55)
Mean Square Error6945T
R-Squared0.30
Significance0.02
Slope(10,537,052)
Total Sum of Squares149475.5T

Gossamer Net Income History

2026-53.4 M
2025-50.9 M
2024-56.5 M
2023-179.8 M
2022-229.4 M
2021-234 M
2020-243.4 M

Other Fundumenentals of Gossamer Bio

Gossamer Bio Net Income component correlations

Gossamer Net Income Driver Correlations

Understanding the fundamental principles of building solid financial models for Gossamer Bio is extremely important. It helps to project a fair market value of Gossamer Stock properly, considering its historical fundamentals such as Net Income. Since Gossamer Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gossamer Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gossamer Bio's interrelated accounts and indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gossamer Bio. If investors know Gossamer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gossamer Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.69)
Revenue Per Share
0.194
Quarterly Revenue Growth
0.402
Return On Assets
(0.34)
Return On Equity
(7.83)
The market value of Gossamer Bio is measured differently than its book value, which is the value of Gossamer that is recorded on the company's balance sheet. Investors also form their own opinion of Gossamer Bio's value that differs from its market value or its book value, called intrinsic value, which is Gossamer Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gossamer Bio's market value can be influenced by many factors that don't directly affect Gossamer Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gossamer Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Gossamer Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gossamer Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Gossamer Bio 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Gossamer Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Gossamer Bio.
0.00
10/28/2025
No Change 0.00  0.0 
In 3 months and 1 day
01/26/2026
0.00
If you would invest  0.00  in Gossamer Bio on October 28, 2025 and sell it all today you would earn a total of 0.00 from holding Gossamer Bio or generate 0.0% return on investment in Gossamer Bio over 90 days. Gossamer Bio is related to or competes with Kalvista Pharmaceuticals, 4D Molecular, Olema Pharmaceuticals, Ventyx Biosciences, Lexicon Pharmaceuticals, Rigel Pharmaceuticals, and Prothena Plc. Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and comme... More

Gossamer Bio Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Gossamer Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Gossamer Bio upside and downside potential and time the market with a certain degree of confidence.

Gossamer Bio Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Gossamer Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Gossamer Bio's standard deviation. In reality, there are many statistical measures that can use Gossamer Bio historical prices to predict the future Gossamer Bio's volatility.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Gossamer Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.142.767.59
Details
Intrinsic
Valuation
LowRealHigh
0.224.359.18
Details
Naive
Forecast
LowNextHigh
0.063.127.95
Details
9 Analysts
Consensus
LowTargetHigh
8.659.5010.55
Details

Gossamer Bio January 26, 2026 Technical Indicators

Gossamer Bio Backtested Returns

Gossamer Bio appears to be unstable, given 3 months investment horizon. Gossamer Bio holds Efficiency (Sharpe) Ratio of 0.0691, which attests that the entity had a 0.0691 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Gossamer Bio, which you can use to evaluate the volatility of the firm. Please utilize Gossamer Bio's Risk Adjusted Performance of 0.0638, market risk adjusted performance of 0.2861, and Downside Deviation of 5.04 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Gossamer Bio holds a performance score of 5. The company retains a Market Volatility (i.e., Beta) of 1.4, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Gossamer Bio will likely underperform. Please check Gossamer Bio's potential upside, as well as the relationship between the accumulation distribution and relative strength index , to make a quick decision on whether Gossamer Bio's current trending patterns will revert.

Auto-correlation

    
  -0.88  

Excellent reverse predictability

Gossamer Bio has excellent reverse predictability. Overlapping area represents the amount of predictability between Gossamer Bio time series from 28th of October 2025 to 12th of December 2025 and 12th of December 2025 to 26th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Gossamer Bio price movement. The serial correlation of -0.88 indicates that approximately 88.0% of current Gossamer Bio price fluctuation can be explain by its past prices.
Correlation Coefficient-0.88
Spearman Rank Test-0.69
Residual Average0.0
Price Variance0.19
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Gossamer Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

1.44 Million

At this time, Gossamer Bio's Accumulated Other Comprehensive Income is comparatively stable compared to the past year.
Based on the recorded statements, Gossamer Bio reported net income of (56.53 Million). This is 116.56% lower than that of the Biotechnology sector and 180.7% lower than that of the Health Care industry. The net income for all United States stocks is 109.9% higher than that of the company.

Gossamer Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gossamer Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gossamer Bio could also be used in its relative valuation, which is a method of valuing Gossamer Bio by comparing valuation metrics of similar companies.
Gossamer Bio is currently under evaluation in net income category among its peers.

Gossamer Bio Current Valuation Drivers

We derive many important indicators used in calculating different scores of Gossamer Bio from analyzing Gossamer Bio's financial statements. These drivers represent accounts that assess Gossamer Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Gossamer Bio's important valuation drivers and their relationship over time.
202120222023202420252026 (projected)
Market Cap846.5M183.5M205.8M204.6M235.3M223.6M
Enterprise Value848.3M297.3M386.2M361.5M415.7M610.9M

Gossamer Bio ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Gossamer Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Gossamer Bio's managers, analysts, and investors.
Environmental
Governance
Social

Gossamer Bio Institutional Holders

Institutional Holdings refers to the ownership stake in Gossamer Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Gossamer Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Gossamer Bio's value.
Shares
Hillhouse Capital Advisors, Ltd.2025-06-30
M
Geode Capital Management, Llc2025-06-30
4.6 M
Alyeska Investment Group, L.p.2025-06-30
4.5 M
Ci Private Wealth Llc2025-06-30
3.7 M
Monaco Asset Management2025-06-30
3.5 M
Opaleye Management Inc2025-06-30
3.5 M
Rock Springs Capital Management Lp2025-06-30
3.3 M
Renaissance Technologies Corp2025-06-30
2.7 M
State Street Corp2025-06-30
2.5 M
Octagon Capital Advisors Lp2025-06-30
18.4 M
Nea Management Company, Llc2025-06-30
18.1 M

Gossamer Fundamentals

About Gossamer Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Gossamer Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gossamer Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gossamer Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Gossamer Stock Analysis

When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.